Vanda Pharmaceuticals | VNDA - Trade Debtors


Vanda Pharmaceuticals reported $47.1M in Trade Debtors for its fiscal quarter ending in December of 2024.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 10.58M 5.55M Dec/2025
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 140.86M 75.6M Dec/2025
J&J USD 21.33B 3.72B Dec/2025
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
Ligand Pharmaceuticals USD 58.1M 15.98M Sep/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 184M 862M Dec/2025
Novartis USD 12.29B 3.3B Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 397M 100M Dec/2025
Takeda JPY 757.92B 55.68B Dec/2025
Teva Pharmaceutical Industries USD 3.71B 101M Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Veracyte USD 44.66M 3.17M Dec/2025